Source: International Congress 2017 – Systemic and airway biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Faner Canet (Barcelona, Spain). Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD. 1020

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial manifestation of systemic inflammation in patients with COPD Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 The link between systemic inflammation and pulmonary hypertension in patients with stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 53s Year: 2005 Evaluation of specific immune complexes in patients with pulmonary sarcoidosis. Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Systemic inflammation and pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 142s Year: 2007 Cytokine regulation of local and systemic inflammation in COPD patients Source: Annual Congress 2010 - Novel markers of lung injury Year: 2010 Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Differences in systemic immune function contribute to exacerbation susceptibility in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Systemic inflammatory reactions in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 38s Year: 2006 Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Non-infectious pulmonary complications in immunocompromised (IC) patients. Associated pulmonary and systemic inflammatory response Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 Comprehensive pulmonary rehabilitation improves systemic inflammation in patients with stable COPD Source: Annual Congress 2007 - Effects of training in rehabilitation Year: 2007 Systemic inflammation in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020 Abnormal systemic cytokine response to a progressive inspiratory loading test in patients with severe chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: Suppl. 45, 87s Year: 2003 Cachexia in patients with acute COPD exacerbations: relationship to pulmonary function, systemic inflammation and oxidative stress Source: Annual Congress 2008 - Comorbidities in COPD Year: 2008 COPD is associated with reduced pulmonary interstitial expression of pentraxin-3 Source: Eur Respir J 2012; 39: 830-838 Year: 2012 Signs of MICA as an innate immune molecule potentially involved in vascular remodelling in patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005